Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Brendan Curti"'
Autor:
Helen Gogas, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz Couselo, Adi Diab, Caio Pereira, Gaëlle Quéreux, Shahneen Sandhu, Brendan Curti, Nikhil I. Khushalani, Matthew H. Taylor, Gregory A. Daniels, Anna Spreafico, Tarek Meniawy, Alfons J. M. Van Den Eertwegh, Yongliang Sun, Yull Arriaga, Ming Zhou, Georgina V. Long, Céleste Lebbé
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract In PIVOT IO 001 (NCT03635983), the combination of the investigational interleukin-2 agonist bempegaldesleukin (BEMPEG) with nivolumab (NIVO) had no added clinical benefit over NIVO monotherapy in unresectable/metastatic melanoma. Pre-defined
Externí odkaz:
https://doaj.org/article/26da8ef263884c9b8a1666837464dce4
Autor:
Brendan Curti, Koustubh Ranade, Laura Collins, Marlana Orloff, Emma Leach, Sarah Stanhope, Adel Benlahrech, Kevin Kim
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/631b1a31539341579031893888fc8433
Autor:
Ning Li, William L Redmond, Brendan Curti, Shuhang Wang, Herui Yao, Erwei Song, Henry Yu, Giorgio Massimini, Ming-Hong Hu, Rongliang Lou, Wanping Geng, Sanlong Wang, Meiling Zhang, Rongchu Chen, Baotian Qin, John Mao, Shaoshan Wang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7b531028babd4a6d95e0a4b089285ad9
Autor:
Brendan Curti, Igor Puzanov, Mateusz Opyrchal, Christopher J Nirschl, Mehmet A Bilen, Kristin Morris, Justin C Moser, Ildefonso Rodriguez Rivera, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2c535f528fe849388924b327f27fc65e
Autor:
Li Zhang, Ning Li, Brendan Curti, Stephen Spurgeon, Elisabeth Heath, Naomi Hunder, Eric Jonasch, Dingwei Ye, Zhu Chen, Melissa Reimers, Stephen Park, Weidong Li, Paolo Caimi, Ulka N Vaishampayan, Benjamin Garmezy, Swetha Kambhampati, Catherine Diefenbach, Noah Kornblum, Weili Zhao, Sharon Ma, Eric Song, Justin A Call
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/76bf6cfb9a414feeb1aa4885de183aec
Autor:
Catherine T. Le, Logan V. Vick, Craig Collins, Cordelia Dunai, Michael K. Sheng, Lam T. Khuat, Isabel Barao, Sean J. Judge, Ethan G. Aguilar, Brendan Curti, Maneesh Dave, Dan L. Longo, Bruce R. Blazar, Robert J. Canter, Arta M. Monjazeb, William J. Murphy
Publikováno v:
JCI Insight, Vol 8, Iss 18 (2023)
Bystander activation of memory T cells occurs via cytokine signaling alone in the absence of T cell receptor (TCR) signaling and provides a means of amplifying T cell effector responses in an antigen-nonspecific manner. While the role of Programmed C
Externí odkaz:
https://doaj.org/article/61038b8528944e2fac44a9057e6d02fd
Autor:
Ann W. Silk, Brendan Curti, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P. Kane, Phoebe Hannon, Christopher Fountain, Jessica Felcher, Andrew Zloza, Howard L. Kaufman, Janice M. Mehnert, David F. McDermott
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionHigh-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents by the U.S. F.D.A. for the treatment of metastatic melanoma. There is limited data using the agents concurrently. The objectives of this study were to
Externí odkaz:
https://doaj.org/article/e180df27cd2646ef8743d38d18aaff92
Autor:
Emma Bigelow, Suchi Saria, Brian Piening, Brendan Curti, Alexa Dowdell, Roshanthi Weerasinghe, Carlo Bifulco, Walter Urba, Noam Finkelstein, Elana J Fertig, Alex Baras, Neeha Zaidi, Elizabeth Jaffee, Mark Yarchoan
Publikováno v:
Cancer Informatics, Vol 21 (2022)
Tumor mutational burden (TMB), a surrogate for tumor neoepitope burden, is used as a pan-tumor biomarker to identify patients who may benefit from anti-program cell death 1 (PD1) immunotherapy, but it is an imperfect biomarker. Multiple additional ge
Externí odkaz:
https://doaj.org/article/5bbf36839b37402ab474076c76e37c58
Autor:
Omid Hamid, Brendan Curti, Craig L Slingluff, Mohammed Milhem, Jose Lutzky, Suthee Rapisuwon, Brian Gastman, Takami Sato, Marcus O Butler, Robert Andtbacka, Eddy Hsueh, Robert Weber, John Glaspy, Sekwon Jang, Sajeve Thomas, Karl D Lewis, Leonel Hernandez-Aya, John Hyngstrom, Adam Berger, Edward Levine, Montaser F Shaheen, Vinay Gupta, Svetomir N Markovic, Tawnya Bowles, Joel Claveau, Prejesh Philips, Shernan G Holtan, William Schmidt, Juan Paramo, Arvinda Padmanabhan, Daniel Milton, Andrew Pecora, Suprith Badarinath, John Keech, Sujith Kalmadi, Pallavi Kumar, Anna Bar, J Thaddeus Beck, Jeffrey B Travers, Catalin Mihalcioiu, Peter Beitsch, Edward C McCarron, Deepti Behl, Brent Blumenstein, Joanna J Peterkin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/5160c99c6dc74e998f952d3b03d4f787
Autor:
Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel, Patricia LoRusso, Amy Weise, Joseph Eder, Brendan Curti, Michael Oberst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. Methods MEDI0680 wa
Externí odkaz:
https://doaj.org/article/cf9d82e0ebcd4aaeac76ef9a975cf4f7